The Radius VSM from Masimo Corp. - FDA-cleared opioid risk alerts on the wrist

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-22, 18:57. Details in the imprint.

The Radius VSM from Masimo sits light on a patient’s wrist, its soft strap digging slightly into the skin as the room hums with quiet ventilator noise, yet it now watches for opioid-induced breathing problems hours before anyone hears a crash alarm.

What the Radius VSM is

The Radius VSM is a wearable, modular patient monitor that wirelessly streams continuous vital signs such as oxygen saturation, pulse rate and respiration to hospital monitoring systems. It is designed to replace tangle-prone bedside cables with a compact wrist unit and small body-worn sensors.

Unlike simple spot-check devices, the Radius VSM can integrate multiple Masimo technologies, including rainbow SET pulse oximetry and other non-invasive parameters, depending on the configuration a hospital chooses. Clinicians see the combined data on central stations, tablets or existing Masimo bedside monitors.

New FDA-cleared opioid alert

On 22 June 2026 Masimo announced FDA 510(k) clearance for a new Radius VSM capability that detects opioid-induced respiratory depression, or OIRD, in hospital patients receiving opioids. The feature uses pattern recognition algorithms on continuous physiological data to flag early signs of breathing suppression.

According to Masimo founder and CEO Joe Kiani, this AI-driven alert is meant to shift monitoring from reactive alarms to proactive warnings, giving clinicians a chance to intervene before oxygen saturation or respiratory rate collapse. Hospitals can integrate the OIRD notification into existing alarm workflows on their Masimo platforms.

How it works at the bedside

In practice, a nurse sees Radius VSM data on a central station: clean trend lines for SpO2, pulse and respiration, then a quiet but insistent notification that the OIRD algorithm detects a risky pattern, even though traditional thresholds are not yet breached. The device itself stays largely unobtrusive on the patient’s arm.

Masimo states that the algorithm evaluates multiple parameters over time rather than a single snapshot, which can reduce false alarms compared with simple threshold-based systems. The goal is to catch subtle hypoventilation under opioid therapy while maintaining alarm fatigue at a manageable level for staff.

Positioning in Masimo’s portfolio

Radius VSM sits alongside Masimo’s Root and Patient SafetyNet platforms as a bridge between fully wired bedside monitors and lightweight ward wearables. For hospital IT teams this consistency means they can roll out the new OIRD function without buying an entirely separate monitoring stack.

Since Masimo sold its Sound United consumer-audio business in late 2025 to refocus on healthcare, tools like Radius VSM have become central to its clinical growth story. The company highlights high-margin professional monitoring as its strategic core going forward.

Pricing, markets and limits

Masimo does not publish a list price for Radius VSM, as it is typically sold within larger monitoring deals that bundle sensors, software and service for hospitals. Industry reports suggest that such wearable monitors are increasingly specified in tenders in North America and selected European markets.

The system is clearly targeted at professional care environments rather than home use, and it requires integration into Masimo’s ecosystem plus clinical oversight. For smaller clinics the up-front investment and IT complexity may be a barrier compared with more basic pulse oximeters.

Context and Masimo share price

All told, the Radius VSM with FDA-cleared OIRD detection underlines Masimo’s push toward AI-enhanced wearable monitoring, tying hardware, algorithms and service revenue together. Masimo Corp. shares (ISIN US5747951003) trade on NASDAQ in US dollars as part of the US medical-technology sector.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.